CoChat
Sign Up
Cited by 318Liver Disease Diagnosis and TreatmentLiver Diseases and ImmunityLiver physiology and pathology

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial†

Leuschner, Ulrich F. H., Lindenthal, Birgit, Herrmann, Günter, Arnold, Joachim C., Rössle, Martin, Cordes, Hans‐Jörg, Zeuzem, Stefan, Hein, Jasper, Berg, Thomas·2010·Hepatology
DOI 10.1002/hep.23727
Open this paper in CoChat — free account

Abstract

UNLABELLED: In uncontrolled clinical studies, ursodeoxycholic acid (UDCA) had a beneficial effect on nonalcoholic steatohepatitis (NASH). However, a large controlled trial using UDCA (13-15 mg/kg/day) was unable to confirm these results. Accordingly, a randomized, placebo-controlled study was initiated with a high dose of UDCA (23-28 mg/kg/day). The allocation of patients and the evaluation of liver histology were performed according to a modified Brunt score and the nonalcoholic fatty liver disease activity score (NAS). With the modified Brunt score, 185 patients with histologically proven NASH were randomized [intention to treat (ITT)], and 147 were treated per protocol (PP). With the NAS, 137 patients were confirmed to have NASH, 48 had borderline NASH, and 1 did not have NASH. The treatment time was 18 months. At entry, the treatment groups were comparable. A second biopsy sample was obtained from 139 of 185 patients (NAS: 107/137). The primary criterion for evaluation was a change in the liver histology; the secondary criteria were single histological variables and liver biochemistry. Significant differences in the overall histology could not be detected between the two treatment groups with the modified Brunt score (P = 0.881) or NAS (P = 0.355). Only lobular inflammation improved significantly (P for the modified Brunt score = 0.011, P for NAS = 0.005). In subgroup analyses, significant improvements in lobular inflammation were also observed in males, younger patients up to 50 years of age, slightly overweight patients, and patients with hypertension and an increased histology score. The fibrosis score did not change (P for ITT = 0.133, P for PP = 0.140). With the exception of gamma-glutamyl transferase, UDCA did not improve laboratory data. CONCLUSION: High-dose UDCA failed to improve the overall histology in patients with NASH in comparison with placebo.

Overview

Integrity signals

Registry

Crossref · 10.1002/hep.23727

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 36 references

Research works printed but not linked: 1

  1. Padda, 1999, The effect of ursodeoxycholic acid (UDCA) treatment on liver tests in patients with non alcohol induced steatohepatitis (NASH), Am J Gastroenterol, 94, A334

Cited by

Sorted by citations

Items 201–300 of 318

Related

See all

Metadata

Authors
Leuschner, U. F. H., Lindenthal, B., Herrmann, G., Arnold, J. C., Rössle, M., Cordes, H., Zeuzem, S., Hein, J., & Berg, T.
Affiliations
  • Krankenhaus Sachsenhausen (DE)
  • Goethe University Frankfurt (DE)
  • Klinikum Ludwigsburg (DE)
  • Agaplesion Diakonieklinikum Rotenburg (DE)
  • University Hospital Leipzig (DE)
Corresponding author
Leuschner, Ulrich F. H.
ORCID
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2010-08
Volume
52
Issue
2
Pages
472-479
ISSN
0270-9139 (ISSN-L)
DOI
10.1002/hep.23727
OpenAlex
W2097677758
Cited by
317
References
36
Citations by year
2026: 9 · 2025: 7 · 2024: 13 · 2023: 14 · 2022: 15 · 2021: 29 · 2020: 17 · 2019: 25 · 2018: 15 · 2017: 21 · 2016: 20 · 2015: 25 · 2014: 23 · 2013: 25 · 2012: 25
FWCI
19.31
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1857 d)
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
ursodeoxycholic acid, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, liver histopathology, lobular inflammation, liver fibrosis, liver biochemistry, gamma-glutamyl transferase
MeSH terms
Adolescent, Adult, Aged, Double-Blind Method, Fatty Liver, Female, Humans, Male, Middle Aged, Ursodeoxycholic Acid, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review